Patients who benefit

AMPLATZER™ SEPTAL
OCCLUDER
STRUCTURAL INTERVENTIONS

The primary treatment option for atrial septal defects (ASD) is percutaneous,
transcatheter closure, and Abbott’s Amplatzer™ Septal Occluder is the proven
standard of care^2,5—with more than 20 years of global clinical experience in ASD closure.¹

The importance of treating patients with Atrial Septal Defects

Patients diagnosed with an ASD, who are indicated for closure with an Amplatzer™ Septal Occluder, exhibit both⁶:

Echocardiographic evidence of ostium secundum ASD
Clinical evidence of right ventricular (RV) volume overload (i.e., ratio of pulmonary to systemic flow > 1.5 or RV enlargement)

“

After receiving ASD closure with the Amplatzer Septal Occluder, Valeria remarks: “If I had not had this procedure done (ASD closure) I would not be able to live a normal life and I would not be like a normal girl”

Valeria - Spain

This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Patient Experience after Atrial Septal Defect Occlusion

Patients typically report symptom improvement after the closure of the ASD. In young children, growth rate can increase, and in children and young adults, LV filling improves. When younger patients are treated—those who have less chamber enlargement before repair—there is greater likelihood of normalization of RV size.⁹

NEW VERSION AVAILABLE
GET THE AMPLATZER™ PORTFOLIO APP

The Amplatzer™ Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.